|
Jun 24
|
Company News for Jun 24, 2024
|
|
Jun 24
|
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
|
|
Jun 21
|
What next for gas prices, how the S&P 500 can reach 6,000: Market Domination
|
|
Jun 21
|
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
|
|
Jun 21
|
These Stocks Moved the Most Today: Nvidia, Microsoft, Trump Media, Sarepta, Palantir, Hertz, Smith & Wesson, and More
|
|
Jun 21
|
Sector Update: Health Care Stocks Gain in Late Afternoon
|
|
Jun 21
|
Sarepta's Stock Soars on Best-Case FDA Decision for its Muscular Dystrophy Treatment
|
|
Jun 21
|
Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More
|
|
Jun 21
|
US indexes open mixed, pharmaceutical stocks climb: Morning Brief
|
|
Jun 21
|
Sarepta Stock Surges On FDA News; Industrial Stock In Buy Zone
|
|
Jun 21
|
Stocks to Watch Friday: Nvidia, Micron, Sarepta, CarMax
|
|
Jun 21
|
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says
|
|
Jun 21
|
Sarepta Gains as FDA Official Overrules Staff to Approve Therapy
|
|
Jun 21
|
Sarepta Stock Surges on Expanded Elevidys Approval. It’s a ‘Best-Case’ Scenario for Shares.
|
|
Jun 21
|
Sarepta surges on expanded approval of muscular dystrophy drug
|
|
Jun 21
|
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
|
|
Jun 13
|
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
|
|
Jun 13
|
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
|
|
Jun 13
|
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
|
|
May 24
|
Implied Volatility Surging for Sarepta (SRPT) Stock Options
|